Renaissance Technologies’s Finch Therapeutics Group, Inc. Common Stock FNCH Stock Holding History

Renaissance Technologies’s Portfolio FNCH Stock Details FNCH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-11,746	Closed	-$42K	–	4235
2023 Q4	$42K	Buy	+11,746	New	+$46.3K	﹤0.01%	3485
2023 Q2	–	Sell	-3,100	Closed	-$37K	–	4411
2023 Q1	$37K	Sell	3,100 -997	-24%	-$13.2K	﹤0.01%	3726
2022 Q4	$59K	Buy	4,097 +2,744	+203%	+$91.8K	﹤0.01%	3767
2022 Q3	$68K	Buy	1,353 +63	+5%	+$4.38K	﹤0.01%	3691
2022 Q2	$110K	Sell	1,290 -210	-14%	-$18K	﹤0.01%	3823
2022 Q1	$226K	Buy	1,500 +244	+19%	+$56.3K	﹤0.01%	3598
2021 Q4	$376K	Buy	+1,256	New	+$482K	﹤0.01%	3231

Other funds holding FNCH

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LSAG

Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Renaissance Technologies's FNCH Position: Q1 2024 in Review

Renaissance Technologies sold out of Finch Therapeutics Group, Inc. Common Stock (FNCH) in Q1 2024, closing a stake of 11,746 shares — an estimated $42K sold.

Renaissance Technologies first reported a position in FNCH in Q4 2021 and held it in 7 quarters. The position peaked at $376K in Q4 2021. 11 funds tracked by Wall St. Rank hold FNCH as of Q1 2024.

Renaissance Technologies reported no remaining Finch Therapeutics Group, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Renaissance Technologies sold 11,746 Finch Therapeutics Group, Inc. Common Stock shares in Q1 2024, an estimated $42K.
Renaissance Technologies first reported a position in Finch Therapeutics Group, Inc. Common Stock in Q4 2021 and held it in 7 quarters.
Renaissance Technologies's Finch Therapeutics Group, Inc. Common Stock position peaked at $376K in Q4 2021.
11 funds tracked by Wall St. Rank held Finch Therapeutics Group, Inc. Common Stock as of Q1 2024.

Based on Renaissance Technologies's 13F filing for Q1 2024, filed 13 May 2024.